No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa

AIDS

Volumn 22, Issue 9, 2008, Pages 1055-1061

  Abu Raddad, Laith J ^a,b   Longini Jr , Ira M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute infection; HIV phase; HIV stage; Infectious disease; Late stage; Latent stage; Mathematical model

Indexed keywords

ADOLESCENT; ADULT; AFRICA; ARTICLE; COITUS; DISEASE COURSE; DISEASE TRANSMISSION; FEMALE; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; PRIORITY JOURNAL; PROBABILITY; SEXUAL BEHAVIOR; VIRUS TRANSMISSION;

CAMEROON; CIRCUMCISION, MALE; DISEASE OUTBREAKS; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MALE; MODELS, STATISTICAL; PROSTITUTION; RISK FACTORS; RISK-TAKING; SEXUAL BEHAVIOR; SEXUAL PARTNERS;

EID: 44449120726     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f8af84     Document Type: Article

References (39)

1. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785-1792.
2. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li CJ, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342:921-929.
3. Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 2005;191:1391-1393.
4. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536.
5. Rapatski BL, Suppe F, Yorke JA. HIV epidemics driven by late disease stage transmission. J Acquir Immune Defic Syndr 2005; 38:241-253.
6. Rapatski BL, Suppe F, Yorke JA. Reconciling different infectivity estimates for HIV-1. J Acquir Immune Defic Syndr 2006; 43:253-256.
7. Nagot N, Delany-Moretlwe S, Mayaud P. Antiherpetic therapy for HIV infection: linking prevention and care. Future HIV Therapy 2007; 1:131-136.
8. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006; 314:1603-1606.
9. Kublin JG, Patnaik P, Jere CS, Miller WC, Hoffman IF, Chimbiya N, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233-240.
10. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-799.
11. Coutinho FA, Lopez LF, Burattini MN, Massad E. Modelling the natural history of HIV infection in individuals and its epidemiological implications. Bull Math Biol 2001; 63:1041-1062.
12. Hyman JM, Li J, Stanley EA. The differential infectivity and staged progression models for the transmission of HIV. Math Biosci 1999; 155:77-109.
13. Ahlgren DJ, Gorny MK, Stein AC. Model-based optimization of infectivity parameters: a study of the early epidemic in San Francisco. J Acquir Immune Defic Syndr 1990; 3:631-643.
14. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7:1169-1184.
15. Koopman JS, Jacquez JA, Welch GW, Simon CP, Foxman B, Pollock SM, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:249-258.
16. Levin BR, Bull JJ, Stewart FM. The intrinsic rate of increase of HIV/AIDS: epidemiological and evolutionary implications. Math Biosci 1996; 132:69-96.
17. Xiridou M, Geskus R, de Wit J, Coutinho R, Kretzschmar M. Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS 2004; 18:1311-1320.
18. Massad E, Burattini MN, Coutinho FA, Lopez LF. Which phase of the natural history of HIV infection is more transmissible? Int J STD AIDS 2002; 13:430-431.
19. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341:394-402.
20. Vella S, Galluzzo MC, Giannini G, Pirillo MF, Andreotti M, Tomino C, et al. Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment. Antiviral Res 2000; 47:189-198.
21. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409.
22. Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148:88-96.
23. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
24. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83.
25. Korenromp EL, de Vlass SJ, Nagelkerke NJ, Habbema JD. Estimating the magnitude of STD cofactor effects on HIV transmission: how well can it be done? Sex Transm Dis 2001; 28:613-621.
26. Brunham RC, Plummer FA. A general model of sexually transmitted disease epidemiology and its implications for control. Med Clin North Am 1990; 74:1339-1352.
27. Morgan D, Whitworth J. The natural history of HIV-1 infection in Africa. Nat Med 2001; 7:143-145.
28. Buve A, Carael M, Hayes RJ, Auvert B, Ferry B, Robinson NJ, et al. The multicentre study on factors determining the differential spread of HIV in four African cities: summary and conclusions. AIDS 2001; 15 (Suppl 4):S127-S131.
29. Hubert JB, Burgard M, Dussaix E, Tamalet C, Deveau C, Le Chenadec J, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS 2000; 14:123-131.
30. Buve A, Carael M, Hayes RJ, Auvert B, Ferry B, Robinson NJ, et al. Multicentre study on factors determining differences in rate of spread of HIV in sub-Saharan Africa: methods and prevalence of HIV infection. AIDS 2001; 15 (Suppl 4):S5-S14.
31. Morison L, Weiss HA, Buve A, Carael M, Abega SC, Kaona F, et al. Commercial sex and the spread of HIV in four cities in sub-Saharan Africa. AIDS 2001; 15 (Suppl 4):S61-S69.
32. Hayes RJ, White RG. Amplified HIV transmission during early-stage infection. J Infect Dis 2006; 193:604-605; author reply 605-606.
33. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959.
34. Pao D, Fisher M, Hue S, Dean G, Murphy G, Cane PA, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 2005; 19:85-90.
35. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, et al. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15:2287-2292.
36. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtypes on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008 (in press).
37. Lutalo T, Gray RH, Wawer M, Sewankambo N, Serwadda D, Laeyendecker O, et al. Survival of HIV-infected treatment-naïve individuals with documented dates of seroconversion in Rakai, Uganda. AIDS 2007; 21 (Suppl 6):S15-S19.
38. Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis 2003; 188:179-193.
39. Gray RH, Li X, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, et al. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004; 189:1209-1215.